Finance

FDA fast-tracks psychedelic drug research following Trump executive order

It's a big shift toward supporting psychedelic-based medicines for treatment-resistant depression, PTSD and substance use disorders, the FDA said.

C
CNBC
April 24, 2026·1 min de lecture
GM
Finance

It's a big shift toward supporting psychedelic-based medicines for treatment-resistant depression, PTSD and substance use disorders, the FDA said.

Article original

FDA fast-tracks psychedelic drug research following Trump executive order

Publié par CNBC

Lire l'article complet